CClinicalTrials.gg
CompletedNCT06417450Updated Aug 22, 2025

Usefulness of NESA Microcurrents in the Treatment of Children With Autism Spectrum Disorders

An interventional study of Non-invasive Neuromodulation and Placebo Non-invasive Neuromodulation in Autism Spectrum Disorder, sponsored by University of Las Palmas de Gran Canaria. Completed at 1 site in Spain. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by University of Las Palmas de Gran Canaria · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Study summary

The term or definition of Autism Spectrum Disorder (ASD) defines a pervasive neurodevelopmental disorder in which deficits in communication and social interaction, altered sensorimotor behaviours, repetitive, restricted and stereotyped interests and activities are observed.

One of the disorders most frequently associated with ASD, and which most affects the quality of life of the child and his or her family, is sleep disorders; it is estimated that between 50 and 80 percent of children with ASD present this alteration and generally continue to suffer from it in adolescence and adulthood; It has also been observed that there is a correlation between sleep problems and an increase in aggressive behaviour, social and emotional deficits and deficits in activities of daily living, which severely affects the child and his or her close family environment; they become emotionally destabilised in a notorious way, and this has a negative impact on their work and productive environment.

The microcurrents generated by the non-invasive neuromodulation device introduce, by means of a non-invasive technique (surface electrodes), electrical energy to normalise the nervous stimulus. This makes it an excellent complementary treatment to the activity of rehabilitation treatment. Its effects are achieved by establishing several input nerve pathways corresponding to the body's dermis, through which the signals are intellectualised in time-space. These signals are the basis for achieving normalisation of the nerve impulse by means of microcurrents.

Read the detailed description

The main objective will be to test the influence of surface neuromodulation applied NESA on sleep disturbances in children with Autism Spectrum Disorders and how this is related to disruptive behaviours and quality of life in the family environment.

It is estimated to take 8 months from the design, management and development of the project, and does not have sources of funding.

02

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • physical therapy modality
  • sleep disorder
  • Quality of Life
03

In context

Autism Spectrum Disorder

1,727 studies on the registry are indexed under Autism Spectrum Disorder; 504 are open to participants now.

This study's enrollment of 40 is below the median of 52 across 1,371 interventional studies indexed under Autism Spectrum Disorder.

Browse Autism Spectrum Disorder studies →

Lead sponsor

University of Las Palmas de Gran Canaria is the lead sponsor of 22 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Children with a diagnosis of Autistic Spectrum Disorder, attending school in the City of San Juan de Dios in Las Palmas de Gran Canaria.
  • Children with symptoms related to sleep disturbances.
  • Children who present episodes of disruptive behaviour.
  • Children who may present sensory alterations or cognitive deficits.
  • Children whose parents sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Present some of the contraindications for treatment with NESA XSIGNAL®: pacemakers, internal haemorrhages, not applying electrodes on skin in poor condition, with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and/or phobia of electricity.
  • If parents do not sign the informed consent form.
  • Presence of uncontrolled convulsions.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Non-invasive Neuromodulation

    Intervention with electrical stimulation: application of 6 electrodes per extremity and an adhesive electrode at C7 level.

    Device: Non-invasive Neuromodulation

  • Placebo comparator
    Placebo Non-invasive Neuromodulation

    Intervention with electrical stimulation: application of 6 electrodes per extremity and an adhesive electrode at C7 level.

    Device: Placebo Non-invasive Neuromodulation

Interventions

  • DeviceNon-invasive Neuromodulation

    Patients receive non-invasive neurostimulation through the Nesa device

  • DevicePlacebo Non-invasive Neuromodulation

    The same protocol described for the experimental group will be applied, but electrical stimulation device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.

06

What researchers measure

Primary outcomes

  1. Change in sleep quality with the Sleep Disturbance Scale for Children (SDSC)

    The Sleep Disturbance Scale for Children (SDSC) will be used. The SDSC is a 26-item scale developed to assess the presence of sleep difficulties in children within the previous six months. The measure is completed by the parent of the child and takes approximately 5-10 min to complete. Item 1 measures the child's average hours of sleep, from 1 ('9 - 11 h') to 5 ('less than 5 h').

    Time frame: Measurement of change: before treatment (baseline), at two months (end of treatment).

  2. Measuring sleep habits with the Children's Sleep Habits Questionnaire scale

    Each scored question is rated on a 3-point scale as occurring "usually" (i.e., 5-7 times within the past week), "sometimes" (i.e., 2-4 times within the past week), or "rarely" (i.e., never or 1 time within the past week).

    Time frame: Measurement of change: before treatment (baseline), at two months (end of treatment).

  3. Change in parent´s sleep quality with the Pittsburgh Sleep Quality Index (PSQI)

    The investigators want to see if there are improvements in the quality, efficiency, and quantity of sleep. The Pittsburgh Sleep Quality Index (PSQI) will be combined to report changes in the patient's sleep quality. Each of the sleep components yields a score ranging from 0 to 3, with 3 indicating the greatest dysfunction. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality. Adding up the average scores of the seven factors gives a global PSQI score from 0 to 21, with 0-4 indicating "good" sleep and 5-21 indicating "poor" sleep

    Time frame: Measurement of change: before treatment (baseline), at two months (end of treatment).

Secondary outcomes

  1. Changes to the Register of Disruptive Behaviour Scores with the Aberrant Behavior Checklist (ABC-C)

    The Aberrant Behavior Checklist (ABC-C) is a 58-item rating scale derived by factor analysis, and its five subscales are labelled as follows: I- Irritability (15 items); II- inactivity-isolation (16 items); III- stereotypies (7 items); IV- Hyperactivity, non-compliance (16 items) and V- inappropriate language (4 items). The ABC-C is easy to use, it is completed by an informant such as a teacher, therapist, monitor, parent or other adult who has regular contact with the patient. Each behavioural item is rated on a four-point scale from 0 (not a problem) to 3 (problem is severe).

    Time frame: Measurement of change: before treatment (baseline), at two months (end of treatment).

  2. Change in the stress level of parents with the Change in the stress level of parents

    The Parenting Stress Index-Short Form (PSI-SF) is one of the most commonly used measures of parenting stress both in clinical and research contexts. The PSI-SF is a 36-item, self-report measure with three subscales: Parental Distress (PD), Parent-Child Dysfunctional Interaction (PCDI), and Difficult Child (DC). To compute the parental stress score, items 1, 2, 5, 6, 7, 8, 17, and 18 should be reverse scored as follows: (1=5) (2=4) (3=3) (4=2) (5=1). The item scores are then summed. Parental stress scores range from 18 to 90, with lower scores indicating lower levels of parental stress.

    Time frame: Measurement of change: before treatment (baseline), at two months (end of treatment).

  3. Change in parental satisfaction with the Parent Satisfaction Questionnaire (PSQ - FS)

    The 19-item PSQ assesses parents' cognitions and perceptions regarding the degree and kind of support they provide to their child following the discovery of sexual abuse. The measure yields a total score and scores on Support and Blame subscales

    Time frame: Measurement of change: before treatment (baseline), at two months (end of treatment).

Other outcomes

  1. Recording of adverse phenomena

    The responses experienced by the participant will be observed during the session. As the procedure is sensory imperceptible and easy to handle, it will allow the participant to carry out activities (school/rehabilitation) simultaneously.

    Time frame: From the start of treatment to the end of treatment (2 months)

07

Study locations

1 site
  • University of Las Palmas de Gran Canaria
    Las Palmas de Gran Canaria, Las Palmas 35016, Spain
08

References and documents

Publications

  • Parr J. Autism. BMJ Clin Evid. 2010 Jan 7;2010:0322. PubMed 21729335 ↗
  • Moss AH, Gordon JE, O'Connell A. Impact of sleepwise: an intervention for youth with developmental disabilities and sleep disturbance. J Autism Dev Disord. 2014 Jul;44(7):1695-707. doi: 10.1007/s10803-014-2040-y. PubMed 24442795 ↗
  • Souders MC, Zavodny S, Eriksen W, Sinko R, Connell J, Kerns C, Schaaf R, Pinto-Martin J. Sleep in Children with Autism Spectrum Disorder. Curr Psychiatry Rep. 2017 Jun;19(6):34. doi: 10.1007/s11920-017-0782-x. PubMed 28502070 ↗
  • Hirata I, Mohri I, Kato-Nishimura K, Tachibana M, Kuwada A, Kagitani-Shimono K, Ohno Y, Ozono K, Taniike M. Sleep problems are more frequent and associated with problematic behaviors in preschoolers with autism spectrum disorder. Res Dev Disabil. 2016 Feb-Mar;49-50:86-99. doi: 10.1016/j.ridd.2015.11.002. Epub 2015 Dec 10. PubMed 26672680 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06417450
Lead sponsor
University of Las Palmas de Gran Canaria
Responsible party
Aníbal Báez Suárez (Clinical Professor, University of Las Palmas de Gran Canaria) — Principal investigator
First posted
May 16, 2024
Start date
May 13, 2024
Primary completion
May 13, 2025
Completion
Jul 13, 2025
Last update
Aug 22, 2025

Study contacts

Aníbal Báez Suárez, PhD
principal investigator · University of Las Palmas de Gran Canaria

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion